Almirall is the lead sponsor of 13 current clinical trials in our Spain, Germany, Poland, Austria, UK, France, Italy, USA, Netherlands, Denmark, Czechia and EU (CTIS) registers. 8 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Lebrikizumab, Tildrakizumab and Adalimumab. The most-studied condition is Eczema.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Almirall as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
2025-521293-34-00 · CTIS ↗ · Skin and Connective Tissue Diseases
Drug: Adalimumab |
Phase 2 | Ongoing | Ireland + 5 more |
|
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
2025-525133-31-00 · Skin and Connective Tissue Diseases
Drug: Lebrikizumab |
Phase 3 | Authorised | Poland, Germany, Portugal + 1 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Inmagene | 2 |
Sponsors with the most current trials registered for this condition.
Almirall is the lead sponsor of 11 current trials on ClinicalTrials.gov in our Spain, Germany, Poland, Austria, UK, France, Italy, USA, Netherlands, Denmark and Czechia registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Lebrikizumab (4), Tildrakizumab (3), Adalimumab (2) and Diclofenac Sodium (1). The number in brackets is how many of its trials name each drug.
Yes. 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.